SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
To evaluate the efficacy and safety of yttrium-90 carbon microspheres versus cTACE in patients with unresectable hepatocellular carcinoma
| Condition(s) | Unresectable Hepatocellular Carcinoma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | To evaluate the efficacy and safety of yttrium-90 carbon microspheres versus cTACE in patients with unresectable hepatocellular carcinoma |
| Who can participate | Inclusion Criteria: 1. Eastern Cooperative Oncology Group performance status ≤ 1; 2. Expected survival time ≥ 3 months; 3. Confirmed hepatocellular carcinoma based on CNLC guidelines; 4. Without extrahepatic metastases, unresectable or refuse surgical resection; 5. At least one well defined tumor (mRECIST 1.1); 6. Tumor burden≤50% of the total liver volume; 7. Child-Pugh score≤7; 8. Adequate organ function: # Blood routine: absolute neutrophil count ≥ 1.5×10\^9/L; platelet≥75×10\^9/L; hemoglobin≥90 g/L; # Liver function: total bilirubin≤2 times upper limit of normal (ULN); alanine transaminase and aspartate aminotransferase≤5.0 ULN; alkaline phosphatase≤2.5 ULN; Albumin\>30 g/L; # Renal function: Cr≤1.5 ULN; creatinine clearance≥50 mL/min; # Coagulation function: international normalized r |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Zhongda Hospital |
| Locations | Nanjing, Jiangsu, China |
| Start date | 2025-04-03 |
| NCT ID | NCT06909708 |
| Official listing | https://clinicaltrials.gov/study/NCT06909708 |